

B. the helper T cell response rate of said human population, wherein a higher proportion of the model human population meeting the requirements of step (ii)(b) predicts a higher helper T cell response rate in said human population.

In another aspect, the disclosure further provides a method of predicting the clinical response rate of a specific or target human population to administration of a pharmaceutical composition, kit or panel of polypeptides comprising one or more polypeptides as active ingredients, the method comprising

(i) selecting or defining a relevant model human population comprising a plurality of individual subjects, each defined by HLA class I genotype;

(ii) determining

(a) for each subject in the model human population whether the one or more active ingredient polypeptides together comprise at least two different amino acid sequences each of which is a T cell epitope capable of binding to at least two HLA class I molecules of the subject, optionally wherein the at least two different amino acid sequences are comprised in the amino acid sequence of two different polypeptide antigens targeted by the active ingredient polypeptide(s);

(b) in the model population the mean number of target polypeptide antigens that comprise at least one amino acid sequence that is

A. a T cell epitope capable of binding to at least three HLA class I molecules of the individual subjects of the model population; and

B. comprised in the amino acid sequence of the active ingredient polypeptide(s); and/or

(c) in the model population the mean number of expressed target polypeptide antigens that comprise at least one amino acid sequence that is

A. a T cell epitope capable of binding to at least three HLA class I molecules of the individual subjects of the model population; and

B. comprised in the amino acid sequence of the active ingredient polypeptide(s); and

(iii) predicting the clinical response rate of said human population, wherein a higher proportion of the model human population meeting the requirements of step (ii)(a), or a higher mean number of target polypeptides in step (ii)(b), or a higher mean number of expressed target polypeptides in step (ii)(c) predicts a higher clinical response rate in said human population.

The disclosure further provides methods of treatment of a human subject in need thereof, the method comprising administering to the subject a polypeptide, pharmaceutical composition or kit of the polypeptides of a panel of polypeptides that has been identified or selected based on their predicted immune or clinical response rate determined as described above; their use in a method of treatment of a relevant human subject; and their use in the manufacture of a medicament for treating a relevant subject.

In another aspect, the disclosure also provides a method of designing or preparing a polypeptide, or a polynucleic acid that encodes a polypeptide, for use in a method of inducing an immune response in a subject of a specific or target human population, the method comprising

- (i) selecting or defining
 - (a) a relevant model human population comprising a plurality of individual subjects each defined by HLA class I genotype and/or by HLA class II genotype; and/or
 - (b) a relevant model human population comprising a plurality of individual subjects each defined by HLA class I genotype and one relevant model human population comprising a plurality of subjects each defined by HLA class II genotype;
- (ii) identifying a fragment of up to 50 consecutive amino acids of a target polypeptide antigen that comprises or consists of
 - A. a T cell epitope capable, in at least 10 percent of the subjects of a model population selected or defined in step (i) that is defined by HLA class I genotype, of binding to at least three HLA class I molecules of the individual subjects;

B. a T cell epitope capable, in at least 10 percent of the subjects of a model population selected or defined in step (i) that is defined by HLA class II genotype, of binding to at least three HLA class II molecules of the individual subjects; or

5 C. a T cell epitope capable, in at least 10 percent of the subjects of a model population selected or defined in step (i) that is defined by HLA class I genotype, of binding to at least three HLA class I molecules of the individual subjects and a T cell epitope capable, in at least 10 percent of the subjects of a model population selected or defined in step (i) that is defined by HLA class II
10 genotype, of binding to at least three HLA class II molecules of the individual subjects;

and

(iii) designing or preparing a polypeptide, or a polynucleic acid that encodes a polypeptide that comprises or consists of one or more polypeptide fragments
15 identified in step (ii), optionally wherein the polypeptide fragment is flanked at the N and/or C terminus by additional amino acids that are not part of the sequence of the target polypeptide antigen.

In yet another aspect, the disclosure refers to a pharmaceutical composition, panel of polypeptides or kit for use in therapy for inducing an immune response in a human subject,

20 wherein the pharmaceutical composition, panel of polypeptides or kit

(a) comprises as active ingredients a first and a second and optionally one or more additional polypeptides, wherein each polypeptide comprises an amino acid sequence that is a T cell epitope capable of binding to at least three HLA class I molecules of at least 10% of subjects in the human population, wherein the T cell epitope of the first, second and optionally any additional
25 regions are different from each other; or

(b) comprises an active ingredient polypeptide comprising a first region and a second region and optionally one or more additional regions, wherein each region comprises an amino acid sequence that is a T cell epitope capable of binding to at least three HLA class I molecules of at least 10% of subjects in the human population, wherein the T cell

epitope of the first, second and optionally any additional regions are different from each other;

and wherein the pharmaceutical composition or kit optionally comprises at least one pharmaceutically acceptable diluent, carrier, or preservative; optionally wherein the therapy is prophylactic.

In yet another aspect, the disclosure refers to a pharmaceutical composition, panel of polypeptides or kit for use in therapy of a subject in need thereof, wherein the pharmaceutical composition, panel of polypeptides or kit

(I) comprises as active ingredients a first and a second peptide and optionally one or more additional peptides, wherein each peptide comprises an amino acid sequence that is an HLA class I-binding T cell epitope wherein at least 10% of human subjects having cancer both

i. express a tumor associated antigen selected from the antigens listed in Table 2 that comprises said T cell epitope; and

ii. have at least three HLA class I molecules capable of binding to said T cell epitope;

wherein said T cell epitope of the first, second and optionally any additional peptides are different from each other. In yet another aspect, the disclosure refers to a pharmaceutical composition, panel of polypeptides or kit for use in therapy of a subject in need thereof, wherein the pharmaceutical composition, panel of polypeptides or kit comprises an active ingredient polypeptide comprising a first and a second region and optionally one or more additional regions, wherein each region comprises an amino acid sequence that is an HLA class I-binding T cell epitope wherein at least 10% of human subjects having cancer both

i express a tumor associated antigen selected from the antigens listed in Table 2 that comprises said T cell epitope; and

ii have at least three HLA class I molecules capable of binding to said T cell epitope;

wherein said T cell epitope of the first, second and optionally any additional regions are different from each other. In yet another aspect, the disclosure refers to a pharmaceutical composition, panel of polypeptides or kit for use in therapy of a subject in need thereof, wherein the pharmaceutical composition, panel of polypeptides or kit

comprises as active ingredients a first and a second polypeptide and optionally one or more additional polypeptides, wherein each polypeptide comprises an amino acid sequence that is an HLA class I-binding T cell epitope, wherein at least 10% of human subjects having a cancer selected from colorectal, breast, ovarian, melanoma, non-melanoma skin, lung, prostate, kidney, bladder, stomach, liver, cervix uteri, oesophagus, non-Hodgkin lymphoma, leukemia, pancreas, corpus uteri, lip, oral cavity, thyroid, brain, nervous system, gallbladder, larynx, pharynx, myeloma, nasopharynx, Hodgkin lymphoma, testis and Kaposi sarcoma both

i express a tumor associated antigen selected from the antigens listed in Table 2 that comprises said T cell epitope; and

ii have at least three HLA class I molecules capable of binding to said T cell epitope; wherein said T cell epitope of the first, second and optionally any additional peptides are different from each other. In yet another aspect, the disclosure refers to a pharmaceutical composition, panel of polypeptides or kit for use in therapy of a subject in need thereof, wherein the pharmaceutical composition, panel of polypeptides or kit

comprises an active ingredient polypeptide comprising a first and a second region and optionally one or more additional regions, wherein each region comprises an amino acid sequence that is an HLA class I-binding T cell epitope, wherein at least 10% of human subjects having a cancer selected from colorectal, breast, ovarian, melanoma, non-melanoma skin, lung, prostate, kidney, bladder, stomach, liver, cervix uteri, oesophagus, non-Hodgkin lymphoma, leukemia, pancreas, corpus uteri, lip, oral cavity, thyroid, brain, nervous system, gallbladder, larynx, pharynx, myeloma, nasopharynx, Hodgkin lymphoma, testis and Kaposi sarcoma both

i express a tumor associated antigen selected from the antigens listed in Table 2 that comprises said T cell epitope; and

ii have at least three HLA class I molecules capable of binding to said T cell epitope; wherein said T cell epitope of the first, second and optionally any additional polypeptides are different from each other;

and wherein the pharmaceutical composition or kit optionally comprises at least one pharmaceutically acceptable diluent, carrier, or preservative; optionally wherein the therapy is prophylactic.

CLAIMS

1. A method of predicting the cytotoxic T cell response rate and/or the helper T cell response rate of a specific or target human population to administration of a polypeptide, or to administration of a pharmaceutical composition, kit or panel of polypeptides comprising one or more polypeptides as active ingredients, the method comprising
 - (i) selecting or defining a relevant model human population comprising a plurality of subjects each defined by HLA class I genotype and/or HLA class II genotype;
 - (ii) determining for each subject in the model human population whether the polypeptide or polypeptides together comprise
 - (a) at least one amino acid sequence that is a T cell epitope capable of binding to at least two HLA class I molecules of the subject; and/or
 - (b) at least one amino acid sequence that is a T cell epitope capable of binding to at least two HLA class II molecules of the subject; and
 - (iii) predicting
 - A. the cytotoxic T cell response rate of said human population, wherein a higher proportion of the model human population meeting the requirements of step (ii)(a) predicts a higher cytotoxic T cell response rate in said human population; and/or
 - B. the helper T cell response rate of said human population, wherein a higher proportion of the model human population meeting the requirements of step (ii)(b) predicts a higher helper T cell response rate in said human population.
2. A method of predicting the clinical response rate of a specific or target human population to administration of a pharmaceutical composition, kit or panel of polypeptides comprising one or more polypeptides as active ingredients, the method comprising
 - (i) selecting or defining a relevant model human population comprising a plurality of individual subjects, each defined by HLA class I genotype;
 - (ii) determining
 - (a) for each subject in the model human population whether the one or more active ingredient polypeptides together comprise at least two different amino acid sequences each of which is a T cell epitope capable of binding to at least two HLA

class I molecules of the subject, optionally wherein the at least two different amino acid sequences are comprised in the amino acid sequence of two different polypeptide antigens targeted by the active ingredient polypeptide(s);

(b) in the model population the mean number of target polypeptide antigens that comprise at least one amino acid sequence that is

A. a T cell epitope capable of binding to at least three HLA class I molecules of the individual subjects of the model population; and

B. comprised in the amino acid sequence of the active ingredient polypeptide(s); and/or

(c) in the model population the mean number of expressed target polypeptide antigens that comprise at least one amino acid sequence that is

A. a T cell epitope capable of binding to at least three HLA class I molecules of the individual subjects of the model population; and

B. comprised in the amino acid sequence of the active ingredient polypeptide(s); and

(iii) predicting the clinical response rate of said human population, wherein a higher proportion of the model human population meeting the requirements of step (ii)(a), or a higher mean number of target polypeptides in step (ii)(b), or a higher mean number of expressed target polypeptides in step (ii)(c) predicts a higher clinical response rate in said human population.

3. The method of claim 1 or claim 2 further comprising repeating the method for one or more further polypeptides, pharmaceutical compositions, kits or panels of polypeptides, and ranking the polypeptides, pharmaceutical compositions, kits or panels of polypeptides according to their predicted cytotoxic

T cell, helper T cell and/or or clinical response rates in said specific or target human population.

4. The method of any one of claims 1 to 3 further comprising selecting or recommending treatment of a subject in need thereof for administration of one or more polypeptides or pharmaceutical compositions or the polypeptides of one or more kits or panels of polypeptides, based on their predicted response rate or response rate ranking.

5. The method of claim 4 wherein (a) a polypeptide, pharmaceutical composition, kit or panel of polypeptides having a high predicted response rate or response rate ranking is selected or recommended for inducing a therapeutic immune response in the subject; or
(b) a polypeptide, pharmaceutical composition, kit or panel of polypeptides having a low predicted response rate or response rate ranking is selected or recommended for avoiding a toxic immune response.

6. A method of designing or preparing a polypeptide, or a polynucleic acid that encodes a polypeptide, for use in a method of inducing an immune response in a subject of a specific or target human population, the method comprising

- (i) selecting or defining
 - (a) a relevant model human population comprising a plurality of individual subjects each defined by HLA class I genotype and/or by HLA class II genotype;
or
 - (b) one relevant model human population comprising a plurality of individual subjects each defined by HLA class I genotype and one relevant model human population comprising a plurality of subjects each defined by HLA class II genotype;
- (ii) identifying a fragment of up to 50 consecutive amino acids of a target polypeptide antigen that comprises or consists of
 - A. a T cell epitope capable, in at least 10percent of the subjects of a model population selected or defined in step (i) that is defined by HLA class I genotype, of binding to at least three HLA class I molecules of the individual subjects;
 - B. a T cell epitope capable, in at least 10 percent of the subjects of a model population selected or defined in step (i) that is defined by HLA class II genotype, of binding to at least three HLA class II molecules of the individual subjects; or
 - C. a T cell epitope capable, in at least 10 percent of the subjects of a model population selected or defined in step (i) that is defined by HLA class I genotype, of binding to at least three HLA class I molecules of the individual subjects and a T cell epitope capable, in at least 10percentage of the subjects of a model population selected or defined in step (i) that is defined by HLA class II genotype, of binding to at least three HLA class II molecules of the individual subjects;

and

(iii) designing or preparing a polypeptide, or a polynucleic acid that encodes a polypeptide that comprises one or more polypeptide fragments identified in step (ii), optionally wherein the polypeptide fragment is flanked at the N and/or C terminus by additional amino acids that are not part of the sequence of the target polypeptide antigen.

7. The method of claim 6, wherein the polypeptide fragment selected in step (ii) is an HLA class I-binding epitope, and the method further comprises selecting a longer fragment of the target polypeptide antigen, which longer fragment comprises or consists of an amino acid sequence that

- A. comprises the fragment selected in step (ii); and
- B. is an HLA class II molecule-binding T cell epitope capable, in a high percentage of the subjects of a model population selected or defined in step (i) that is defined by HLA class II genotype, of binding to at least three, or the most possible HLA class II molecules of the individual subjects;

and wherein the fragment identified in step (ii) comprises or consists of said longer fragment.

8. The method of claim 6 or claim 7, comprising identifying one or more further fragments of the same or one or more different target polypeptide antigens, wherein each polypeptide fragment is a T cell epitope capable of binding to at least three HLA class I molecules or at least three HLA class II molecules of at least one subject in the model population; and ranking the fragments by

- (i) the percentage of subjects in the model population that express at least three HLA class I molecules capable of binding to the fragment;
- (ii) the percentage of subjects in the model population that are predicted to express both the target polypeptide antigen comprising the fragment and at least three HLA class I molecules capable of binding to the fragment;
- (iii) the percentage of subjects in the model population that express at least three HLA class II molecules capable of binding to the fragment;
- (iv) the percentage of subjects in the model population that are predicted to express both the target polypeptide antigen comprising the fragment and at least three HLA class II molecules capable of binding to the fragment;

- (v) the percentage of subjects in the model population that express at least three HLA class I molecules and at least three HLA class II molecules capable of binding to the fragment; or
- (iv) the percentage of subjects in the model population that are predicted to express both the target polypeptide antigen comprising the fragment and at least three HLA class I molecules and at least three HLA class II molecules capable of binding to the fragment.
9. The method of any one of claims 6 to 8, wherein the method comprises selecting one or more of the polypeptide fragments based on their ranking, and designing or preparing the polypeptide to comprise or the polynucleic acid to encode the one of more selected polypeptide fragments.
- 10.. The method of any one of claims 6 or to 9, further comprises designing or preparing a polypeptide, a panel of polypeptides, or a pharmaceutical composition or kit comprising one or more polypeptides as active ingredients for use in a method of inducing an immune response in a subject of the specific or target human population, wherein the polypeptide(s) or active ingredient polypeptides comprises at least two polypeptide fragments, optionally between 2 and 15 polypeptide fragments, selected according to the method of any one of claims 6 to 9.
11. The method of claim 10, wherein the two or more or each of the fragments are from different target polypeptide antigens, optionally different target polypeptide antigens selected from the antigens listed in Tables 2 to 6 and/or different cancer associated antigens, optionally wherein one or more or each of the cancer associated antigens are cancer testis antigens (CTAs).
12. The method of claim 10 or claim 11, wherein two or more or each of the fragments are arranged in the polypeptide end to end.
13. The method of claim 12, wherein the method further comprises screening all of the neoepitopes formed at the join between any two of the selected polypeptide fragments arranged end to end in a single polypeptide to eliminate peptides comprising a neoepitope amino acid sequence that

- (i) corresponds to a fragment of a human polypeptide expressed in healthy cells;
- (ii) is a T cell epitope capable of binding, in more than a threshold percentage of human subjects, to at least two HLA class I molecules expressed by individual subjects; or
- (iii) meets both requirements (i) and (ii).

14. The method of any of claims 6 to 13, wherein the one or more polypeptides have been screened to eliminate polypeptides comprising an amino acid sequence that

- (i) corresponds to a fragment of a human polypeptide expressed in healthy cells; or
- (ii) corresponds to a fragment of a human polypeptide expressed in healthy cells and is a T cell epitope capable of binding to at least two HLA class I molecules of the subject.

15. A pharmaceutical composition, panel of polypeptides or kit for use in therapy for inducing an immune response in a human subject, wherein the pharmaceutical composition, panel of polypeptides or kit

- (a) comprises as active ingredients a first and a second and optionally one or more additional polypeptides, wherein each polypeptide comprises an amino acid sequence that is a T cell epitope capable of binding to at least three HLA class I molecules of at least 10% of subjects in the human population, wherein the T cell epitope of the first, second and optionally any additional regions are different from each other; or
- (b) comprises an active ingredient polypeptide comprising a first region and a second region and optionally one or more additional regions, wherein each region comprises an amino acid sequence that is a T cell epitope capable of binding to at least three HLA class I molecules of at least 10% of subjects in the human population, wherein the T cell epitope of the first, second and optionally any additional regions are different from each other;

and wherein the pharmaceutical composition or kit optionally comprises at least one pharmaceutically acceptable diluent, carrier, or preservative; optionally wherein the therapy is prophylactic.

16. The pharmaceutical composition, panel of polypeptides or kit for use of claim 15, wherein

(a) the amino acid sequence of one or more or each of the T cell epitopes is from a polypeptide selected from the antigens listed in Tables 2 to 6, or is a cancer associated antigen, optionally wherein one or more or each of the cancer associated antigens is a CTA; and/or

(b) the amino acid sequence of two or more or each of the T cell epitopes is from a different polypeptide selected from the antigens listed in Tables 2 to 6, and/or different cancer associated antigens, optionally wherein one or more or each of the cancer associated antigens are CTAs.

17. A pharmaceutical composition, panel of polypeptides or kit for use in therapy of a subject in need thereof, wherein the pharmaceutical composition, panel of polypeptides or kit

(I) comprises as active ingredients a first and a second peptide and optionally one or more additional peptides, wherein each peptide comprises an amino acid sequence that is an HLA class I-binding T cell epitope wherein at least 10% of human subjects having cancer both

- i. express a tumor associated antigen selected from the antigens listed in Table 2 that comprises said T cell epitope; and
- ii. have at least three HLA class I molecules capable of binding to said T cell epitope;

wherein said T cell epitope of the first, second and optionally any additional peptides are different from each other.

18. A pharmaceutical composition, panel of polypeptides or kit for use in therapy of a subject in need thereof, wherein the pharmaceutical composition, panel of polypeptides or kit comprises an active ingredient polypeptide comprising a first and a second region and optionally one or more additional regions, wherein each region comprises an amino acid sequence that is an HLA class I-binding T cell epitope wherein at least 10% of human subjects having cancer both

- i express a tumor associated antigen selected from the antigens listed in Table 2 that comprises said T cell epitope; and
- ii have at least three HLA class I molecules capable of binding to said T cell epitope;

wherein said T cell epitope of the first, second and optionally any additional regions are different from each other.

19. A pharmaceutical composition, panel of polypeptides or kit for use in therapy of a subject in need thereof, wherein the pharmaceutical composition, panel of polypeptides or kit comprises as active ingredients a first and a second polypeptide and optionally one or more additional polypeptides, wherein each polypeptide comprises an amino acid sequence that is an HLA class I-binding T cell epitope, wherein at least 10% of human subjects having a cancer selected from colorectal, breast, ovarian, melanoma, non-melanoma skin, lung, prostate, kidney, bladder, stomach, liver, cervix uteri, oesophagus, non-Hodgkin lymphoma, leukemia, pancreas, corpus uteri, lip, oral cavity, thyroid, brain, nervous system, gallbladder, larynx, pharynx, myeloma, nasopharynx, Hodgkin lymphoma, testis and Kaposi sarcoma both

- i express a tumor associated antigen selected from the antigens listed in Table 2 that comprises said T cell epitope; and
- ii have at least three HLA class I molecules capable of binding to said T cell epitope;

wherein said T cell epitope of the first, second and optionally any additional peptides are different from each other,

20. A pharmaceutical composition, panel of polypeptides or kit for use in therapy of a subject in need thereof, wherein the pharmaceutical composition, panel of polypeptides or kit comprises an active ingredient polypeptide comprising a first and a second region and optionally one or more additional regions, wherein each region comprises an amino acid sequence that is an HLA class I-binding T cell epitope, wherein at least 10% of human subjects having a cancer selected from colorectal, breast, ovarian, melanoma, non-melanoma skin, lung, prostate, kidney, bladder, stomach, liver, cervix uteri, oesophagus, non-Hodgkin lymphoma, leukemia, pancreas, corpus uteri, lip, oral cavity, thyroid, brain, nervous system, gallbladder, larynx, pharynx, myeloma, nasopharynx, Hodgkin lymphoma, testis and Kaposi sarcoma both

- i express a tumor associated antigen selected from the antigens listed in Table 2 that comprises said T cell epitope; and
- ii have at least three HLA class I molecules capable of binding to said T cell epitope;

wherein said T cell epitope of the first, second and optionally any additional polypeptides are different from each other;

and wherein the pharmaceutical composition or kit optionally comprises at least one pharmaceutically acceptable diluent, carrier, or preservative; optionally wherein the therapy is prophylactic.

21. The polypeptide, panel of polypeptides, pharmaceutical composition or the active ingredient polypeptides of a kit according to any one of claims 15 to 20, for use in therapy of a human subject in need thereof, wherein the polypeptide, panel of polypeptides, pharmaceutical composition or the active ingredient polypeptides of the kit are to be administered to the subject, and wherein the subject has been determined to express at least three HLA class I molecules and/or at least three HLA class II molecules capable of binding to the polypeptide or to one or more of the active ingredient polypeptides of the pharmaceutical composition or kit.

22. The polypeptide, panel of polypeptides, pharmaceutical composition or the active ingredient polypeptides of a kit of claim 21, wherein the subject has been determined to express at least three HLA class I and/or at least three HLA class II molecules capable of binding to a threshold minimal number of different T cell epitopes of the polypeptide, or the active ingredient polypeptides of the pharmaceutical composition or kit.

23. The polypeptide, panel of polypeptides, pharmaceutical composition or the active ingredient polypeptides of a kit of claim 21 or claim 22, wherein the active ingredient polypeptides of the pharmaceutical composition, kit or panel of polypeptides have been determined to together comprise at least two different sequences each of which is a T cell epitope capable of binding to at least three HLA class I molecules of the subject, optionally wherein the at least two different amino acid sequences are comprised in the amino acid sequence of two different polypeptide antigens targeted by the active ingredient polypeptide(s).

24. The polypeptide, panel of polypeptides, pharmaceutical composition or the active ingredient polypeptides of a kit of any one of claims 21 to 23, wherein the pharmaceutical composition has been determined to have higher than a threshold minimum likelihood of

inducing a clinical response in the subject, wherein one or more of the following factors corresponds to a higher likelihood of clinical response:

- (a) presence in the active ingredient polypeptide(s) of a higher number of amino acid sequences and/or different amino acid sequences that are each a T cell epitope capable of binding to at least three HLA class I of the subject;
- (b) a higher number of target polypeptide antigens, comprising at least one amino acid sequence that is both
 - A. comprised in an active ingredient polypeptide; and
 - B. a T cell epitope capable of binding to at least three HLA class I of the subject; optionally wherein the target polypeptide antigens are expressed in the subject, further optionally wherein the target polypeptides antigens are in one or more samples obtained from the subject;
- (c) a higher probability that the subject expresses target polypeptide antigens, optionally a threshold number of the target polypeptide antigens and/or optionally target polypeptide antigens that have been determined to comprise at least one amino acid sequence that is both
 - A. comprised in in an active ingredient polypeptide; and
 - B. a T cell epitope capable of binding to at least three HLA class I of the subject;and/or
- (d) a higher number of target polypeptide antigens that the subject is predicted to express, optionally a higher number of target polypeptide antigens that the subject expresses with a threshold probability, and/or optionally the target polypeptide antigens that have been determined to comprise at least one amino acid sequence that is both
 - A. comprised in in an active ingredient polypeptide; and
 - B. a T cell epitope capable of binding to at least three HLA class I of the subject.

25. The polypeptide, panel of polypeptides, pharmaceutical composition or the active ingredient polypeptides of a kit of claim 24, wherein the likelihood of a clinical response has been determined by a method comprising

- (i) identifying which polypeptide antigens targeted by the active ingredient polypeptide(s) comprise an amino acid sequence that is both
 - A. comprised in in an active ingredient polypeptide; and

B. a T cell epitope capable of binding to at least three HLA class I of the subject;
(ii) using population expression data for each antigen identified in step (i) to determine the probability that the subject expresses one or more of the antigens identified in step (i) that together comprise at least two different amino acid sequences of step (i); and
(iii) determining the likelihood that the subject will have a clinical response to administration of the administration of the pharmaceutical composition, kit or panel of polypeptides, wherein a higher probability determined in step (ii) corresponds to a more likely clinical response.

26. A system comprising

- (a) a storage module configured to store data comprising the class I and/or class II HLA genotypes of each subject of a model population of human subjects; and the amino acid sequence of one or more test polypeptides; wherein the model population is representative of a test target human population; and
- (b) a computation module configured to identify and/or quantify the amino acid sequences in the one or more test polypeptides that are capable of binding to multiple class I HLA molecules of each subject in the model population and/or the amino acid sequences in the one or more test polypeptides that are capable of binding to multiple class II HLA molecules of each subject in the model population.

27. The system of claim 26 further comprising

- (c) an output module configured to display
 - (i) a prediction of the cytotoxic T cell response rate and/or the helper T cell response rate of the test target human population to administration of the one or more polypeptides, or one or more pharmaceutical compositions comprising the one or more polypeptides as active ingredients; or
 - (ii) a prediction of the clinical response rate of the test target human population to a method of treatment comprising administration of one or more pharmaceutical compositions comprising the one or more polypeptides as active ingredients.